Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

British Journal of Cancer

Volumn 106, Issue 12, 2012, Pages 1945-1952

  Kususda, Y ^a   Miyake, H ^a   Gleave, M E ^b   Fujisawa, M ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

clusterin; OGX 011; renal cell carcinoma; sorafenib

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CLUSTERIN; CUSTIRSEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LETHAL DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERIN; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; PYRIDINES; THIONUCLEOTIDES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862010313     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.209     Document Type: Article

References (42)

1. Ammar H, Closset JL (2008) Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 283: 12851-12861
2. Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS (2010) Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 9: 2090-2101
3. Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ael-F Ahmed, Fujisawa M (2011) Expression of cell cycle-associated proteins in nonmuscle-invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urol Oncol 29: 495-501
4. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99: 274-280 (Pubitemid 46103103)
5. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 20-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296 (Pubitemid 41535369)
6. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 4247-4254
7. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E (2008) A phase I study of OGX-011, a 20-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833-839 (Pubitemid 351231167)
8. Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY (2009) Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymalto-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 21: 704-711
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134 (Pubitemid 46089673)
10. Hara I, Miyake H, Gleave ME, Kamidono S (2001) Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 92: 1220-1224 (Pubitemid 33133492)
11. Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-847
12. Jackson JK, Gleave ME, Gleave J, Burt HM (2005) The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis 8: 229-238 (Pubitemid 41759147)
13. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63: 3575-3584 (Pubitemid 36793038)
14. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H (2005) Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int 96: 895-899 (Pubitemid 41391404)
15. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME (2011) Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 71: 5838-5849
16. Lane BR, Rini BI, Novick AC, Campbell SC (2007) Targeted molecular therapy for renal cell carcinoma. Urology 69: 3-10 (Pubitemid 46161691)
17. Miyake H, Hara I, Gleave ME, Eto H (2004) Protection of androgendependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61: 318-323 (Pubitemid 39564276)
18. Miyake H, Hara I, Kamidono S, Gleave ME (2001a) Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7: 4245-4252 (Pubitemid 34044651)
19. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I (2002) Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 167: 703-706 (Pubitemid 34074570)
20. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I (2001b) Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 5: 105-111 (Pubitemid 32848102)
21. Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M (2009) Clinical outcome of combined immunotherapy with interferon-alpha and lowdose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 27: 598-603
22. Miyake H, Monia BP, Gleave ME (2000a) Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 86: 855-862 (Pubitemid 30350202)
23. Miyake H, Nelson C, Rennie PS, Gleave ME (2000b) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170-176 (Pubitemid 30058748)
24. Miyake H, Nelson C, Rennie PS, Gleave ME (2000c) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60: 2547-2554 (Pubitemid 30262451)
25. Miyake H, Pollak M, Gleave ME (2000d) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60: 3058-3064 (Pubitemid 30395835)
26. Miyake H, Tolcher A, Gleave ME (1999) Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 59: 4030-4040
27. Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME (2005) Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 7: 171-179 (Pubitemid 40315994)
28. Parton M, Gore M, Eisen T (2006) Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 24: 5584-5592 (Pubitemid 46631339)
29. Rini BI, Rathmell WK, Godley P (2008) Renal cell carcinoma. Curr Opin Oncol 20: 300-306 (Pubitemid 351507551)
30. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M (2005) Increased Hsp27 after androgen ablation facilitates androgenindependent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 65: 11083-11093 (Pubitemid 41713379)
31. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J (2006) Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13: 12-19
32. So A, Hadaschik B, Sowery R, Gleave M (2007) The role of stress proteins in prostate cancer. Curr Genomics 8: 252-261 (Pubitemid 47240702)
33. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller Jr WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272-1280
34. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835-844 (Pubitemid 44480537)
35. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140
36. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME (2005) A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698 (Pubitemid 41685303)
37. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8: 3276-3284 (Pubitemid 35155041)
38. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3: 360-367 (Pubitemid 32801886)
39. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY (2005) Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7: 909-915 (Pubitemid 41486292)
40. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY (2010) Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther 9: 1831-1841
41. Zoubeidi A, Chi K, Gleave M (2010a) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16: 1088-1093
42. Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME (2010b) Clusterin facilitates COMMD1 and I-kB degradation to enhance NF-kB activity in prostate cancer cells. Mol Cancer Res 8: 119-130